COMMUNIQUÉS West-GlobeNewswire

Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
03/05/2024
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in [...]
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03/05/2024
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the [...]
10 Barrel Brewing Introduces Pub Cerveza: a New Twist on ‘Cheap Fun.’ Series
03/05/2024
Ahead Of Cinco De Mayo, 10 Barrel’s Award-Winning Brew Team Introduces Pub Cerveza, A Traditional Mexican Style Lager BEND, Ore., May 03, 2024 (GLOBE NEWSWIRE) -- 10 Barrel Brewing Co. ("10 Barrel Brewing Co." or "10 [...]
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
03/05/2024
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today [...]
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
03/05/2024
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025 Phase 2a clinical [...]
Rapid Micro Biosystems Reports First Quarter 2024 Financial Results
03/05/2024
Reports first quarter 2024 total revenue of $5.6 million , representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/05/2024
RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired [...]
Augmedix to Participate in Upcoming Investor Conferences in May and June 2024
03/05/2024
SAN FRANCISCO, May 03, 2024 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced that its management team will participate in the following [...]
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
03/05/2024
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company [...]
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
03/05/2024
— Company to present an update of its ongoing monotherapy and combination Phase 1/1b trial of WTX-124 in advanced or metastatic solid tumors at ASCO — — Company plans to present interim, first-in-human clinical data [...]
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine
03/05/2024
– Trial did not meet primary endpoint – IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a [...]
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
03/05/2024
FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer [...]
Galera Adopts Limited Duration Stockholder Rights Agreement
03/05/2024
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to [...]
Aveanna to Participate at the Barclays Leveraged Finance Conference
03/05/2024
ATLANTA, May 03, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Barclays Leveraged Finance Conference in Austin, TX on May [...]
Immuron Director Resignation
03/05/2024
MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from [...]
PCI Biotech Holding ASA - Notice of Annual General Meeting 2024
03/05/2024
Oslo, Norway 3 May 2024 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 24 May 2024 at 10:00am (CEST). The notice and proposed [...]
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
03/05/2024
MILAN, Italy, May 03, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for [...]
Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
03/05/2024
Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has [...]
Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
03/05/2024
For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35 [...]

Pages